Abstract An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB 1 , CB 2 ) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB 2 activation. Development of CB 2 agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB 2 activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.
Introduction
The cannabinoids are a group of terpenophenolic compounds present in the marijuana plant, Cannabis sativa. At present, three general types of cannabinoids have been identified: phytocannabinoids present uniquely in the cannabis plant, endogenous cannabinoids produced in humans and animals, and synthetic cannabinoids generated in a laboratory (Sarfaraz et al. 2008) . It is worth noting that Cannabis sativa produces over 80 cannabinoids (Console-Bram et al. 2012) . The broader definition of cannabinoids refers to a group of substances that are structurally related to Δ 9 -tetrahydrocannabinol (Δ 9 -THC) or that bind to cannabinoid receptors. The chemical definition includes a variety of distinct chemical classes: the classical cannabinoids structurally related to THC, the non-classical cannabinoids, the aminoalkylindoles, the eicosanoids related to the endocannabinoids, quinolines and arylsulphonamides (Woelkart et al. 2008; Console-Bram et al. 2012) , and additional compounds that do not fall into these standard classes, but bind to cannabinoid receptors (CB). Multifaceted effects of marijuana can be singled out aiming at evaluation of the potential medical value of marijuana and cannabinoids in specific human diseases, with minimal undesired side effects.
Nomenclature of cannabinoid receptors (CB)
There are two well-characterized CB with distinctly different physiological properties. The psychoactive effects of cannabinoids are associated with the CB 1 receptor; the CB 2 receptor mainly mediates anti-inflammatory and immunomodulatory actions (Miller and Stella 2008) .
CB 1
Cannabinoid receptor 1 (CB 1 ) was discovered by Devane et al. 1988 (Devane et al. 1988) . CB 1 cDNA was cloned by Matsuda et al. (1990) from rats using a homology approach to G-protein-coupled receptors (GPCR). Subsequently, CB 1 receptors have been found in other vertebrates as well. The genes for mouse, rat and human CB 1 receptors (CNR1) are located on chromosomes 4, 5 and 6, respectively. The CB 1 receptor is widely distributed throughout the brain regions, especially the frontal cortex, the limbic system, including the hippocampus and amygdala, sensory and motor areas, hypothalamus, pons and medulla (Ashton et al. 2007; Ashton and Moore 2011) .
Human CB 1 shares 94 % amino acid sequence identity with rodent CB 1 (Anday and Mercier 2005) . In addition to full-length CB 1 receptor, two splice variants, human CB 1 a and human CB 1 b, have been described. Both splice variants have altered ligand binding and activation properties compared to full length CB 1 , and are expressed at very low levels in different tissues (Ryberg et al. 2005) . In contrast, another group demonstrated no significant differences between the three variants (full-length and two splice variants) in pharmacological characteristics, such as binding affinity, functional potency, and efficacy of several CB 1 agonists (Xiao et al. 2008 ). The functional significance of different human cannabinoid CB 1 receptor variants remains to be clarified.
The majority of high CB 1 -expressing cells are GABAergic (gamma-aminobutyric acid) neurons belonging mainly to the cholecystokinin-positive and parvalbumin-negative type of interneurons (basket cells) and, to a less extent, to the midproximal dendritic inhibitory interneurons. Only a fraction of low CB 1 -expressing cells is GABAergic. In the hippocampus, amygdala and entorhinal cortex areas, CB 1 mRNA is present at low but significant levels in many non-GABAergic neuronal cells (Marsicano and Lutz 1999) .
CB 2
The second cannabinoid receptor (CB 2 ) was isolated from human myeloid cells in 1992 (Munro et al. 1993) . Soon afterwards, CB 2 was identified in other species, such as mouse, rat, bovine and zebra fish. The CB 2 gene is located on chromosome 1 and 4 in humans and mice, respectively. Unlike the mouse CB 2 gene, which is intron-less, the human gene has been reported to have two splice variants (Liu et al. 2009 ). The longer variant human CB 2 a, comprised of exon 1a, exon 1b and exon 3, is mostly expressed in testis (about 100-fold more compared to spleen or leukocytes). It is also detected in various regions of the brain (Liu et al. 2009 ). The shorter variant, human CB 2 b, consisting of exon 2 and exon 3, is expressed mostly in the spleen and leukocytes, 100-and 30-fold higher, respectively, when compared to CB 2 b expression in the brain (Liu et al. 2009 ). Immune cells express high levels of CB 2 and there is a hierarchy of CB 2 expression within the immune system (B cells > natural killer cells > monocytes > neutrophils > CD8 lymphocytes > CD4 lymphocytes) (Nunez et al. 2004; Yao and Mackie 2009) . The level of expression is dependent on the activation state of the cell and the type of stimuli. Stimulation of splenocytes with LPS leads to CB 2 mRNA down-regulation, whereas CD40 costimulation results in CB 2 mRNA up-regulation (Lee et al. 2001) . CB 2 receptor sequences are less conserved throughout evolution compared to CB 1 receptors. CB 2 and CB 1 receptors share about 44 % identity in humans at the level of amino acids (Liu et al. 2009; Console-Bram et al. 2012) . Humans and mice share about 82 % identity in amino acid sequence of CB 2 (Anday and Mercier 2005) , whereas mice and rat share 93 % identity. Human, rat and mouse sequences diverge at the Cterminus. The mouse protein is 13 amino acids shorter, while the rat protein is 50 amino acids longer than the human (Console-Bram et al. 2012) . Diversity in CB 2 sequences between species can possibly explain differential effects of CB 2 agonists in human and rodent models (Fig. 1) .
Structural similarities and differences of CB 2 and CB 1
Cannabinoid receptors are integral membrane proteins whose amino acid sequences are characterized by seven hydrophobic segments containing α-helical patterns. CBs belong to a group of rhodopsin-like seven-transmembrane (7TM) GPCRs (Palczewski et al. 2000) . CBs share the structural characteristics of other GPCRs: an extracellular N-terminus that is glycosylated, seven transmembrane α-helixes with extracellular and intracellular loops, and an intracellular C-terminus ). While CB 1 and CB 2 are encoded by different genes, they exhibit 44 % amino acid identity throughout the whole protein (Fig. 1) . Since CBs are intrinsic membrane proteins, they are difficult to crystallize for X-ray study. Although their crystal structures are not available, homology models built by using bovine rhodopsin as a template, along with resolution NMR and computer modeling, have revealed that the most important differences between CB 1 and CB 2 with respect to their interaction with the surrounding lipid environment are located in the TM7 juxtamembrane domain (Dainese et al. 2008) . CB 1 presents a hydrophobic surface at the helix Ihelix VII interface that is suitable for a specific interaction with cholesterol and palmitic acid, whereas CB 2 displays a negatively charged region within TM7, which is rather unfavorable for any interaction with lipids. Arg302 in CB 2 TM7 (homologous to Arg401 in CB 1 ) is not available for any interaction with cholesterol or with G-proteins (Xie and Chen 2005) . Despite the ability to be activated by the same endocannabinoids and trigger the same signaling pathways, CB 2 is independent of membrane cholesterol content (Bari et al. 2006) .
In every TM domain, there are residues that have been probed for their importance in ligand binding or signal transduction. CB 2 helix III is in contact with the other helixes and plays an important role in the regulation of cannabinoid activities (Xie et al. 2003) . CB 2 Ser112 has been shown to be crucial for recognition of several cannabinoid ligands (based on mutagenesis studies) (Tao et al. 1999) . The homologous residue in the CB 1 TM3 is Gly195 (Xie et al. 2003) . Unlike the CB 1 receptor, in which Lys192 plays an important role for the binding of most cannabinoid ligands, the homologous residue Lys109 in CB 2 TM3 does not appear to be a key residue (Tao et al. 1999; Xie et al. 2003) . Mutagenesis studies indicate that the TM4 domain in CB 2 plays a more important role for the recognition of the cannabinoid ligand that in CB 1 . The CB 2 -selective antagonist, SR144528, completely fails to antagonize the CB 2 in S161A or S165A mutants, which is explained by existence of alanines in the homologous two sites of TM4 of the CB 1 Fig. 1 Multiple alignment and homology of human and mouse CB 1 and CB 2 receptors. Sequence alignment was performed using ClustalW tool (http://www.ebi.ac.uk/Tools/ msa/clustalw2/). The following symbols denote the degree of conservation observed in each column: "*" means that the residues are identical in all sequences, ":" means that conserved substitutions have been observed, and "." means that semi-conserved substitutions are observed receptor (Xie et al. 2003) . To date, studies of the CB 2 have been limited by the lack of a three dimensional structure, leaving many unanswered questions about interactions at the molecular level with its ligands as well as the nature of the receptor active site(s) (Xie and Chen 2005) . Knowledge of the three-dimensional structure of CB 2 should greatly aid in the rational design of specific CB 2 ligands possessing therapeutic activities, but devoid of undesirable side effects. The dissimilarities between the two receptors could be exploited to design CB 2 -specific ligands in the future.
Medical marijuana
Medical marijuana refers to the parts of the cannabis plant used as a physician-recommended form of herbal therapy or as medicine (synthetic analogs of cannabinoids). In the US recently, use of medical marijuana has surged in the 18 states and the District of Columbia that permit its use. The cannabis plant has a long history of use as a medicine dating back to 2737 B.C. (Ben Amar 2006) . Cannabis sativa contains over 80 different chemical constituents (Molina et al. 2011; Console-Bram et al. 2012 ). There are three phytocannabinoids ( Fig. 2) : THC, cannabidiol (CBD) and cannabinol (CBN). THC is a primary component of cannabis, responsible for the psychoactive effects of the plant; it has mild analgesic and antioxidant activities (Hampson et al. 1998; Molina et al. 2010) . CBD represents up to 40 % of the extract of medicinal cannabis. It has been shown to relieve cough, congestion and nausea, convulsion, inflammation and anxiety, and has been shown to be effective in treating multiple sclerosis (MS), anxiety attacks and schizophrenia (Crippa and Zuardi 2006; Zuardi et al. 2006a, b; Kogan et al. 2007; Mechoulam et al. 2007; Lakhan and Rowland 2009) . CBN is a breakdown product of THC and acts as a weak agonist of CB 1 and CB 2 because of lower affinity than THC toward receptors (Mahadevan et al. 2000) .
There are several medications (plant extracts or synthetic cannabinoid analogues of THC alone or in combination with CBD) that have been approved for medicinal use. Nabilone® was approved in the US and Canada in 1985 as an anti-nausea treatment for patients undergoing cancer chemotherapy (Todaro 2012) . Sativex® was approved in Canada and the UK for treatment of neuropathic pain in MS and pain associated with cancer (Russo et al. 2007; Sastre-Garriga et al. 2007 ). Sativex® has been also approved for MS-associated spasticity in many countries, such as New Zealand, UK, Austria, Czech Republic, Denmark, Germany, Sweden, Israel, Italy and Spain (Leussink et al. 2012 ). In the majority of cases, administration of cannabinoids (natural or synthetic analogs) results in improvement of symptoms of MS, especially spasticity, muscle pain, tremors and bladder control. However, there were differences in the actions of orally administered versus inhaled cannabinoids, probably due to variable absorption of orally administered cannabinoids (Maurer et al. 1990; Russo et al. 2007 ). Several studies have been done on the pharmacokinetics of cannabinoids during different routes of drug administration. Smoking, the major route, provides a rapid and efficient Fig. 2 Prototypical structures of natural and synthetic cannabinoids method for drug delivery from the lungs to the brain, contributing to its abuse potential. The number, duration and spacing of the puffs, as well as holding time and inhalation volumes, greatly affect the degree of exposure (Heishman et al. 1989; Azorlosa et al. 1992) . Synthetic THC, Dronabinol (Marinol®), is usually taken orally, but may also be administered rectally. In addition, abuse is being common by the oral route. Absorption is slower when cannabinoids are ingested, with lower and delayed peak THC concentrations (Law et al. 1984; Huestis 2007) . To prevent first-pass metabolism by the liver, Sativex® is administered sublingually, via the oromucosal route. The oromucosal form of administration has the advantage that the first-pass effects are reduced and, compared to smoking, the maximum plasma THC levels are lower and increase more slowly (Karst et al. 2010; Leussink et al. 2012 ). Because MS is considered to be a relapsing chronic inflammatory disease of the CNS, beneficial anti-inflammatory effects of cannabinoids would provide much needed MS symptom relief. Clinical benefits for the use of cannabinoids in MS patients were also supported by studies in animal models of MS (Baker et al. 2001; Pryce and Baker 2005; Mestre et al. 2009 ).
CB 1 antagonists (AM251 and SR141716A) lead to changes in efflux of noradrenaline and dopamine in various brain regions, leading to antidepressant effects (Tzavara et al. 2003; Witkin et al. 2005) . These studies suggest the possibility of use of cannabinoids in the treatment of mood disorders, such as depression, anxiety, manic depression and posttraumatic stress (Ashton and Moore 2011) .
Marinol® (Dronabinol) was approved by the US and Canada in 1985 for patients undergoing cancer chemotherapy to relieve nausea associated with treatment. In 1992, it was approved for treatment of anorexia associated with AIDSrelated weight loss (Dejesus et al. 2007; Todaro 2012) .
Cannabinoids are increasingly being used for treatment of migraine headaches in patients that are not responding to the serotonin 1D agonist, sumatripan (Krymchantowski and Jevoux Cda 2007) . Dronabinol has been shown to inhibit the 5-HT3 receptor involved in emetic and pain responses (Fan 1995) . A patent has been filed for the use of Dronabiniol for treatment of migraines (Barbato 2007) . Canasol® is used for reduction of intraocular pressure in glaucoma (Crandall et al. 2007) . Cannabinoid compounds applied topically show hypotensive and neuroprotective effects in mice and monkeys (Williams et al. 2007; Yazulla 2008) . In 1992, the FDA approved the use of Dronabinol to stimulate appetite in AIDS patients suffering from wasting syndrome. This triggered further interest in the development of cannabinoid antagonists that would reduce appetite. Rimonabant has been shown to suppress appetite, producing reduction in body weight (Pi-Sunyer et al. 2006) . Dronabinol has been shown to be a potent drug for treatment of HIV-associated sensory neuropathy, the most common peripheral nerve disorder complicating HIV-1 infection (Abrams et al. 2007 ).
Synthetic cannabinoid agonists
Synthetic cannabinoids are functionally similar to THC, the active part of cannabis. Like THC, they bind to the same cannabinoid receptors in the brain and other organs as the endogenous ligands, anandamide and 2-arachidonylglycerol, which interact with both CB 1 and CB 2 receptors. More correctly designated as cannabinoid receptor agonists, synthetic cannabinoid agonists were developed over the past 40 years as therapeutic agents, often for the treatment of pain. However, it proved difficult to separate their desired properties from unwanted psychoactive effects.
Although often referred to simply as synthetic cannabinoids, many of the substances are not structurally related to the so-called "classical" cannabinoids, i.e., compounds like THC, based on dibenzopyran. The cannabinoid receptor agonists form a diverse group, but most are lipid-soluble, non-polar, and consist of 22 to 26 carbon atoms; they would therefore be expected to volatilize readily when smoked. A common structural feature is a side-chain, where optimal activity requires more than four and up to nine saturated carbon atoms. The first figure shows the structure of THC, while the others show examples of synthetic cannabinoid receptor agonists, all of which have been found in "Spice" or other smoking mixtures. The synthetic cannabinoids fall into seven major structural groups (Fig. 2 ):
Compounds in groups 1-5 (JWH compounds) were largely synthesized by Huffman et al. over the past 15 years (Huffman et al. 1996; Wiley et al. 1998; Huffman et al. 2000; Huffman et al. 2003; Huffman et al. 2005; Huffman et al. 2006; Huffman et al. 2010) . The sixth group, cyclohexylphenols, were developed by Pfizer during the 1970's and 1980's (Carissimi et al. 1976) . The classical cannabinoids (seventh group) is the oldest; synthesis began in the 1960's following the identification of the chemical structure of THC Gaoni 1965, 1967; Gaoni and Mechoulam 1971) . In general, the agonists show little selectivity between CB 1 and CB 2 , while antagonist compounds are highly selective (>1000 fold selective for CB 1 vs. CB 2 and vice versa with nanomolar affinity at the relevant receptor) (Console-Bram et al. 2012) . The selectivity of these antagonists allows the discrimination of CB 1 -vs. CB 2 -mediated effects in vitro and in vivo. Despite the existence of numerous non-selective agonists, there are some that exhibit selectivity. For example, HU-308 is a highly selective CB 2 agonist with nanomolar affinity at CB 2 and >1000 fold selectivity for CB 2 vs. CB 1 . If a compound shows >100 fold selectivity, it is classified as a selective agonist (Console-Bram et al. 2012) .
CB signaling-CB-ligand interactions CB 2 , as with the rest of the GPCRs, signals through the three main components of the MAPK pathway, namely, ERK, JNK and p38 (Howlett et al. 2002) . However, activation of CB receptor coupling to MAPKs is dependent on cellular content. A wide range of activation and inhibition has been observed dependent on cell type, cell differentiation status and co-modulators of MAPK cascades (Howlett 2005) . CB 2 agonism decreased CXCR4-activation mediated G-protein activity and MAPK phosphorylation. Furthermore, CB 2 agonists altered cytoskeletal reorganization, by decreasing Factin levels, impairing productive infection (Costantino et al. 2012) . Signaling events associated with inflammatory responses in endothelial cells and monocytes are complex; few studies have addressed potential mechanisms of antiinflammatory CB 2 stimulation. Gertsch et al. investigated intracellular signaling pathways triggered in monocytes by LPS-triggered TNFα and IL-1β production that were suppressed by CB 2 agonist. LPS treatment of human monocytes led to a rapid phosphorylation of p38 and JNK1/2 (Gertsch et al. 2008 ) and CB 2 agonist reduced Erk1/2 and JNK1/2 activation (phosphorylation) (Gertsch et al. 2008 ). Whether or not CB 2 modulates ion channels has been controversial. Felder and colleagues (Felder et al. 1995) suggested that CB 2 does not modulate potassium or high-voltage calcium channels. More recent work indicates that CB 2 agonists do modulate these channels and earlier results were due to functional selectivity of the ligands used (Atwood et al. 2012) . CB 2 affects additional signaling pathways, including activation of phospholipase C, leading to release of calcium (Shoemaker et al. 2005) , regulation of small G proteins (such as Rho, Rac and cdc42) (Kurihara et al. 2006) , and activation of JNK via the phosphatidyl inositol 3 kinase (PI3K)/Akt pathway (Viscomi et al. 2009; Atwood et al. 2012) . In human umbilical vein endothelial cells, cannabidiol could evoke phosphorylation of p44/42 MAPK and PKB/Akt via PI3K pathway (Offertaler et al. 2003) .
GPCRs are regulated at many levels. In general, once they are activated by ligand binding, their signaling is attenuated by a desensitization process, followed by internalization. Desensitization involves G protein receptor kinasemediated phosphorylation of multiple serine or threonine residues of GPCR, followed by binding of the β-arestins. This protein complex is usually localized to clathrin-coated pits or caveoli where it is internalized. The internalized receptor might be transported to endosomes for dephosphorylation and returned to the plasma membrane for the next signaling event or directed to lysosomes for degradation (Atwood et al. 2012) . Little is known about the processes involved in CB 2 adaption to chronic activation. Most of the knowledge comes primarily from cell lines over-expressing CB 2 . Although the levels of expression in those systems significantly exceed in vivo CB 2 levels, the use of expression systems provides very valuable information (Atwood et al. 2012) .
CB 2 receptor expression in immune and neuroimmune cells

Anti-inflammatory effects of cannabinoids
The two well-characterized CBs possess different physiological properties. The psychoactive effects of cannabinoids are associated with CB 1 ; CB 2 mainly mediates anti-inflammatory and immunomodulatory actions (Miller and Stella 2008) . Identification of CB 1 and CB 2 resulted in the recognition of endogenous cannabinoids (endocannabinoids) (Pacher et al. 2006) . Two endocannabinoid metabolizing enzymes were identified: fatty acid amine hydrolase (FAAH) and monoacylglycerol lipase. CB 1 agonists possess neuroprotective properties via diminishing excitotoxicity in postsynaptic neurons (Marsicano et al. 2003) , enhancing vasodilation through CB 1 in vascular smooth muscle and the inhibition of endothelin-1 (Ronco et al. 2007) , and decreasing the release of pro-inflammatory mediators including nitric oxide (NO) and tumor necrosis factor (TNFα) in the acute phase of injury (Fernandez-Lopez et al. 2006; Panikashvili et al. 2006) . Besides their involvement in controlling excitotoxicity and inflammation, compelling evidence shows that CB 1 receptors in the CNS play an important role in neuroprotection (Sanchez and Garcia-Merino 2011) . CB 1 -deficient mice were more susceptible to experimental autoimmune encephalomyelitis (EAE), had more neurodegeneration and had worse recovery, compared to wild type mice (Maresz et al. 2007) . The presence of CB 1 in neurons, but not in Tcells, was an essential requisite for cannabinoid-mediated neuroprotection in EAE. The therapeutic limitations of CB 1 agonists are related to the very short window of their beneficial actions and psychoactive effects at effective doses. CB 2 agonists are devoid of psychoactive activities. Because neuroinflammation plays a significant role in essentially all neurodegenerative processes, CB 2 stimulation became an attractive target for development of neuroprotective therapies. CB 2 is expressed in different types of leukocytes mediating cannabinoid anti-inflammatory effects and immunomodulation (McKallip et al. 2002a, b) .
Cannabinoid induced immunomodulation
The mechanism of cannabinoid-induced immunomodulation has been studied in both in vitro and in vivo systems; however, still many questions remain unanswered. It is known that cannabinoids bind to CB 1 and CB 2 inhibiting adenylate cyclase activity and preventing forskolin-stimulated cAMP activation. This process leads to decreased activity of protein kinase A and subsequently lesser binding of transcription factors to CRE consensus sequences (Condie et al. 1996; Rieder et al. 2010) . Cannabinoids clearly modulate immune responses during inflammatory processes and their immunomodulatory effects have been studied in many disease models such as MS, diabetes, septic shock, rheumatoid arthritis, and others (Tables 1 and 2) . Results of animal studies show that cannabinoids exert their immunomodulatory properties in four ways: i) induction of apoptosis, ii) suppression of cell proliferation, iii) inhibition of proinflammatory cytokine/chemokine production and increase in anti-inflammatory cytokines, and iv) induction of regulatory T cells (Rieder et al. 2010) . It has been shown that THC inhibits proliferation of human lymphocytes in culture (Schwarz et al. 1994 ) and leads to apoptosis of murine macrophages and T cells (Zhu et al. 1998 ). McKallip and colleagues showed that THC affects naïve lymphocytes to a greater degree than activated lymphocytes (McKallip et al. 2002b) . It was also noted that activated lymphocytes had less expression of CB 2 , thereby explaining the decreased sensitivity of activated lymphocytes to THC (McKallip et al. 2002b ). JWH-015, a CB 2 synthetic agonist, inhibited proliferation in T and B cells in a dose-dependent manner and induced apoptosis in splenocytes and thymocytes (Lombard et al. 2007; Rieder et al. 2010 ). Derocq and colleagues (Derocq et al. 1995) demonstrated that the activity of cannabinoids is not restricted to immunomodulation, and in nanomolar concentrations of synthetic (CP55,940 and WIN55212-2) and natural (THC) cannabinoids increase proliferation of B cells co-stimulated with anti-CD40-antibodies, while at micromolar range (1-100 μM) the same cannabinoids inhibited proliferation (Derocq et al. 1995) . Interestingly, cannabinol and THC protected human B lymphoblastoid cell line from serum-deprived cell-death and oxidative stress in sub-micromolar concentrations (Chen and Buck 2000) . The fact that activation of CB 2 triggers apoptosis in immune cells suggests that targeting CB 2 may be a novel approach to the treatment of inflammatory and autoimmune diseases. CB 2 expression in CNS and its mediated anti-neuroinflammatory responses CB 2 expression has been detected in microglia. Carlisle et al. (Carlisle et al. 2002) found CB 1 and CB 2 mRNA in brain tissue and in primary rat microglia cultures. CB 2 expression in microglia is up-regulated during activation. Neuroprotective effects of CB 2 agonists are associated with suppression of microglia activation (Klegeris et al. 2003; Eljaschewitsch et al. 2006 ) via inhibiting the release of neurotoxic factors and by decreasing neuronal cell damage in cell or tissue culture models.
Increased expression of CB 2 under neuroinflammatory conditions was found in human brain (Benito et al. 2008) . Prominent CB 2 upregulation was reported in brain tissues affected by MS, amyotrophic lateral sclerosis (ALS), Down syndrome and Alzheimer's disease (AD) (Benito et al. 2005 , Table 1 Anti-inflammatory effects of CB 2 activation on immune and neuroimmune cells Microglia interfered with expression of CCR2 and iNOS ) Microglia inhibited migration of microglial cells to HIV Tat protein (Fraga et al. 2011) 2007, 2008; Yiangou et al. 2006; Solas et al. 2012) . Enhanced CB 2 expression was detected on microglia, perivascular macrophages and T cells in simian immunodeficiency virus encephalitis, a model of HIV-1 infection that paralleled FAAH over-expression in astrocytes (Benito et al. 2005) . Increased expression of CB 2 on microglia/perivascular macrophages and brain microvascular endothelial cells were found in HIV-1 encephalitis, brain endothelium in HIV + cases (without encephalitis) and very little in non-infected control human brains (Persidsky et al. 2011) . CB 2 agonist prevented neuronal injury during neuroinflammation via upregulation of mitogenactivated protein kinase phosphatase-1 that resulted in Erk1/2 inhibition (Eljaschewitsch et al. 2006) . CB 2 stimulation specifically reduced iNOS production via inhibition of ERK-1/2 phosphorylation in microglia during CNS inflammation (Merighi et al. 2011) . These findings have relevance to anti-inflammatory effects of CB 2 stimulation in brain. CB 2 -mediated regulation of this pathway could be very important for cannabinoid regulation of neuroinflammation. Anti-inflammatory and neuroprotective effects of cannabinoids have been confirmed in animal models for MS, AD, stroke, ALS, and other animal models of diverse inflammatory diseases (summarized in Table 2 ). In summary, cannabinoids can be neuroprotective via their immunomodulatory properties, which have been mainly attributed to CB 2 receptors.
CB receptors in leukocytes and endothelium: relevance to HIV infection Cannabinoids can affect different pro-inflammatory events associated with HIV infection, such as: i) chemotaxis of immune cells, ii) activation of endothelium and leukocyte infiltration into tissues, iii) injury of endothelial barriers, like the blood brain barrier (BBB), and iv) HIV-1 infection of susceptible cells. CB 2 appears to play a major role in leukocyte migration. Human monocytes treated with the synthetic CB 2 agonist, JWH-015, showed diminished migration in response to the chemokines, CCL2 and CCL3, via down-regulation of their receptors and inhibition of IFNγ-induced ICAM-1 expression. Leukocyte migration mediated by RhoA activation was inhibited by CB 2 agonists (Kurihara et al. 2006) . Cannabinoids could reduce inflammation by interfering with the action of other chemoattractants (Montecucco et al. 2008) . Cannabinoids have been reported to inhibit chemokine-induced chemotaxis of various cell types including neutrophils, lymphocytes, macrophages, monocytes and microglia (Miller and Stella 2008) . Recently, it has been shown that CB 2 agonist affected dendritic cell migration in vitro and in vivo, primarily through the inhibition of matrix metalloproteinase-9 expression (Adhikary et al. 2012) .
In addition to putative effects on leukocytes, antiinflammatory properties of CB agonists may be related to their actions on the endothelium. CB 2 has been found in brain endothelium (Golech et al. 2004; Lu et al. 2008) and in endothelial cells from other organs (Rajesh et al. 2007 ). Synthetic CB 2 agonists (JWH-133, HU-308) reduced TNFα-induced activation of human coronary artery endothelial cells in vitro. CB 2 agonists reduced secretion of MCP-1 and attenuated monocyte transendothelial migration (Rajesh et al. 2007 ). Those results are relevant to CB 2 antiinflammatory effects.
Lu and colleagues (Lu et al. 2008 ) demonstrated that HIV-1 gp120 caused secretion of substance P and dysfunction of brain endothelial cells (Ca 2+ influx, decreased barrier tightness, decrease in tight junction (TJ) expression) that was prevented by non-selective CB 1 /CB 2 or CB 1 agonists. These compounds diminished monocyte migration across endothelial monolayers pretreated with gp120. The molecular mechanism underlying the beneficial effects of CB agonists was not investigated. Because CB 2 agonists modulate immune cell migration, they represent a promising pharmacological approach for development of anti-inflammatory therapeutics. Fraga and colleagues (Fraga et al. 2011) found that CB 2 inhibited migration of microglial cells toward HIV Tat protein in a mouse BV-2 microglia-like cell model. In addition, the level of the β-chemokine receptor CCR3 was reduced and its localization was altered.
Our group investigated the effects of CB 2 receptor agonists (JWH133 and O1966) on leukocyte-brain endothelial cell interactions. Using primary human brain microvascular endothelial cells and human monocytes, we showed diminished adhesion of leukocytes to activated endothelium and down-regulation of adhesion molecules. In an animal model of systemic inflammation, leukocyte adhesion was significantly attenuated in postcapillary ) Stroke (ischemia and reperfusion) (Zhang et al. 2007 Murikinati et al. 2010 ; Tuma and Steffens 2012) EAE Alcoholic liver disease (Louvet et al. 2011) venules in animals treated with CB 2 agonists. BBB injury and increased permeability were prevented . The CB 2 agonist, JWH133, was shown to inhibit HIV-1 infection in primary CD4+ T lymphocytes by altering T cell actin dynamics via inactivation of the actin-modulating protein, cofilin. Actin rearrangements are essential for productive infection. CB 2 agonist did not alter CXCR4 expression, T cell activation or viral fusion (Costantino et al. 2012) . We showed that CB 2 agonists diminished HIV replication and HIV LTR activation in monocyte-derived macrophages (personal communication). Cannabimimetic drugs are of particular relevance to HIV-1 associated neurocognitive disorders (HAND) because of their clinical and illicit use in patients with AIDS. The cannabinoid receptor agonist, Win55,212-2, inhibited HIV-1 gp120-induced IL-1β production and synapse loss in a manner reversed by CB 2 receptor antagonist. In contrast, Win55,212-2 did not inhibit synapse loss elicited by exposure to the HIV-1 protein Tat. These results indicate that cannabinoids prevent the impairment of network function produced by gp120 and, thus, might have therapeutic potential in HAND (Kim et al. 2011 ). Molina and colleagues (Molina et al. 2010; Molina et al. 2011 ) demonstrated that that chronic Δ 9 -THC treatment decreased plasma and cerebrospinal fluid (CSF) viral load and tissue inflammation significantly reducing morbidity and mortality of simian immunodeficiency virus-infected macaques. THC treatment led to better maintenance of body weight without any alterations in immune responses (Molina et al. 2010 ). Win55,212-2 has been shown to inhibit HIV-1 expression in CD4 + lymphocytes and microglial cell cultures in a time-and dose-dependant manner (Peterson et al. 2004 ). Taken together, these studies point to potential therapeutic benefits of CB stimulation in treatment of HIV-1 infection.
Summary
The full potential of CB 2 agonists as therapeutic agents remains to be realized. Despite some inadequacies of preclinical models to predict clinical efficacy in humans and differences between the signaling of human and rodent CB 2 receptors, the development of selective CB 2 agonists may open new avenues in therapeutic intervention. Such interventions would aim at reducing the release of pro-inflammatory mediators particularly in chronic neuropathologic conditions such as HAND or MS. Further studies are needed to delineate the therapeutic effects of CB 2 agonists in current efforts to legalize the use of marijuana for medical purposes.
